March 14, 2015
Crowne Plaza® Times Square - Manhattan
1605 Broadway (at 49th Street)
New York, NY 10019

The 8^th Annual Interdisciplinary Prostate Cancer Congress^® and Other Genitourinary Malignancies is a one-day educational meeting that brings together the top experts from key specialties involved in the care of patients with prostate cancer to discuss state-of-the-art treatments and current guidelines, debate controversies and clinical challenges, and review recent trial data and emerging therapeutic approaches with the potential to impact clinical practice.

Today, the interdisciplinary care of prostate cancer has become a reality, and urologists along with radiation, surgical, and medical oncologists are all involved in the management of these patients. In order to provide optimal care, it is essential that all members of the treatment team stay up-to-date on current trends and emerging data, not just in their own area, but also in the related specialties. The Interdisciplinary Prostate Cancer Congress^® and Other Genitourinary Malignancies provides an opportunity for clinicians to receive concise didactic updates on best practices and investigational strategies in each of these topical areas, accompanied by practical case discussions moderated by an expert panel in a multidisciplinary tumor board-like environment.

This activity is supported by educational grants from Astellas and Medivation, Inc., Bayer HealthCare Pharmaceuticals, and sanofi-aventis U.S.

Physicians' Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource^®, LLC designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity is directed toward medical oncologists, radiation oncologists, surgeons, and urologists involved in the treatment and management of patients with prostate cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals interested in the treatment of prostate cancer may also participate.

At the conclusion of this activity, participants should be better prepared to:

• Review evidence-based strategies for the care of patients with multiple lines of therapy, including monotherapy, combinations, or sequencing of therapies
• Choose appropriate genomic tests to guide treatment decisions
• Evaluate emerging clinical data regarding new agents and evolving strategies

The following individuals have no relevant financial relationships with commercial interests to disclose:

Mitchell C. Benson, MD; Leonard G. Gomella, MD, FACS; Tom Henricks; Richard G. Stock, MD

The staff of Physicians’ Education Resource®, LLC: Beth Cameron, PhD; Ann C. Lichti, CHCP; and Emily Valko Lohrmann

The following individuals have relevant financial relationships with commercial interests to disclose:

• Robert Dreicer, MD, MS, FACP, FASCO – Consultant: Medivation, Genentech, Merck, Astellas
• Celestia S. Higano, MD, FACP – Consultant: Bayer HealthCare, Dendreon, Genentech, Johnson & Johnson, AbbVie, Astellas, Ferring, Medivation, Orion, Pfizer
• Primo N. Lara, Jr, MD – Grant/Research Support: Millennium, Aragon, Janssen, Polaris, OncoGeneX, GSK, Genentech; Consultant: Janssen, Clovis, Astex, USOS, Exelixis, ImmunoGen, Pfizer, Teva, Medivation
• Daniel Petrylak, MD – Grant/Research Support: OncoGeneX, Progenics, Johnson & Johnson, Millennium, Celgene, Dendreon, Sanofi; Consultant: Bayer, Bellicum, Dendreon, sanofi -aventis, Johnson & Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer
• Mario Sznol, MD – Consultant: Genentech-Roche, Bristol Myers-Squibb, AstraZeneca/MedImmune, Pfizer, Novartis, Kyowa Hakko Kirin, Amgen (none in past 12 months), Merus, SeattleGenetics, Immune; Shareholder: Amphivena and Adaptive Biotechnologies